Most Recent Articles by Stan Grossman
A survey showed 67.3% of patient advocacy organizations received industry funding, while 11.9% received more than half of their funding from industry.
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
More Articles by Stan Grossman
Neurology Advisor Articles
- Minocycline May Slow Progression From Clinically Isolated Syndrome to Multiple Sclerosis
- Brain Inflammation Observed in Obsessive-Compulsive Disorder
- Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease
- Growing Old Without Alzheimer's Pathology: What's the Secret?
- Traumatic Brain Injury May Increase Later Risk of Dementia